Ixico wins £2mln extension to Huntington's disease study
“This decision validates our technology and endorses the service provided"
Company
IXICO PLC
LON:IXI
IXICO is no ordinary Imaging Contract Research Organisation (iCRO). By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and a 20-year track record as an end-to-end iCRO. IXICO addresses the complex biomarker challenges associated with neurodegenerative conditions, expertly managing and analysing neuroimaging clinical trials in areas such as Alzheimer’s, Parkinson’s, Huntington's and other rare diseases.
263 stories · page 6 of 14
Archive
Small Cap Wrap - Petards Group, GYG Group, Verditek and more...
Wheaton precious Metals (TSE:WPM) - Proposed secondary listing on bringing one of the world’s largest precious metal streaming companies to the London Stock Exchange. Due Q 2020 AB Ignitis grupe—leading utility and renewable energy company
IXICO joins neuroimaging consortium focused on Friedreich’s Ataxia
FA is a rare genetic disease that causes difficulty walking, a loss of sensation in the arms and legs and impaired speech
IXICO to supply its imaging expertise to leading Alzheimer’s trial
The UK group will collect and analyse Positron Emission Tomography images generated by the Global Alzheimer's Platform Foundation’s Bio-Hermes study
IXICO raises guidance after strong second half
The upgrading of earnings expectations further underpins the company's confidence in its ability to invest to deliver further profitable medium and long-term growth
IXICO reinstated as a 'buy' by Cenkos
"In this current period of high uncertainty, we believe IXICO offers the opportunity to invest in a high growth, high forward visibility, profitable business"
IXICO eyes better margins and double-digit revenue growth in 2020 and 2021
Chief executive Giulio Cerroni said the group's remote access business model helped mitigate potential disruption during the pandemic
Ixico in very strong position going forward, says broker
Over the mid- to longer-term, a significant opportunity remains for the company, added the broker.
IXICO earnings rise in first half as order book continues to strengthens
The brain imaging specialist said it had ended the six months to March 31, 2020, with a £15.3mln order book, however, this has risen to over £22mln in April
IXICO makes strong start to the year with revenues up 33%; cash position strong
The company's order book currently stands at £22.5mln following a significant new deal last week
IXICO jumps as it inks 'substantial' new contract
The deal for a late-phase open label study into Huntington’s disease brings the total value of new deals signed for the current financial year-to-date to £15mln
Ixico wins second imaging services contract with Vaccinex
On an existing project with Vaccinex in Huntington's disease, positive imaging results obtained in an interim analysis indicated the drug's potential in additional therapeutic areas
IXICO to present scientific poster on enhancing imaging analysis accuracy for Huntington's Disease
The poster presentation will be seen at the CHDI Foundation 15th Annual 2020 Huntington's Disease Therapeutics Conference held from 24-27 February, 2020 in Palm Springs, California, USA
Ixico joins forces with Alzheimer's disease neuroimaging initiative
ADNI is a longitudinal multicentre study looking to develop clinical, imaging and biochemical biomarkers for the early detection and tracking of the chronic neurodegenerative disease
IXICO has “market leading position” and “impressive commercial traction”, says investment fund BGF
The comments were made during a Q&A session with Paul Stevens, a member of BGF’s investment team who focuses on identifying opportunities among AIM-listed companies
IXICO reveals £2.4mln expansion of study programmes with two large pharma client contracts
The firm said it has agreed around a £1.8mln extension to a Phase III study in Huntington's Disease, previously announced in September 2018
IXICO gains as it achieves first year of profitability since AIM listing
The neuroscience analytics firm swung to an EBITDA profit of £500,000 from a £600,000 loss in the prior year, while revenues rose to a record level of £7.6mln
Archive
FTSE 100 closes higher midweek as equities rebound on trade deal hopes
Britain's blue chip benchmark closed almost 30 points higher, or 0.41% at 7,188 on the day
IXICO to present three posters at California Alzheimer's conference
The AI data analytics group specialises in aiding neuroscience clinical drug development
IXICO jumps as it secures three new contracts, appoints new chief business officer.
The three deals, one with an existing client and two with new firms, carry a combined initial value of around £1.2mln